期刊
DRUGS OF TODAY
卷 51, 期 12, 页码 705-718出版社
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2015.51.12.2421058
关键词
Invasive fungal infection; Azole; Triazole; Fluconazole; Itraconazole; Posaconazole; Voriconazole; Ravuconazole; Albaconazole; Isavuconazole; Isavuconazonium sulfate; Efinaconazole; CYP51; Lanosterol 14 alpha-demethylase; Cytochrome P450
Invasive fungal infections and systemic mycosis, whether from nosocomial infection or immunodeficiency, have been on an upward trend for numerous years. Despite advancements in antifungal medication, treatment in certain patients can still be difficult for reasons such as impaired organ function, limited administration routes or poor safety profiles of the available antifungal medications. The growing number of invasive fungal species becoming resistant to current antifungal medications is of appreciable concern. Triazole compounds containing one or more 1,2,4-triazole rings have been shown to contain some of the most potent antifungal properties. Itraconazole and fluconazole were some of the first triazoles synthesized, but had limitations associated with their use. Second-generation triazoles such as voriconazole, posaconazole, albaconazole, efinaconazole, ravuconazole and isavuconazole are all derivatives of either itraconazole or fluconazole, and designed to overcome the deficiencies of their parent drugs. The goal of this manuscript is to review antifungal agents derived from triazole.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据